Synapse - Howard Scher

Search Within

Howard Scher

Results (1133)

Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)

Meeting Abstract

Anand, A.; Danila, D. C.; Heller, G.; Herkal, A.; Patel, C.; Khanin, R.; Schultz, N.; Lilja, H.; Fleisher, M.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Molecular biomarkers for patients with castration-resistant prostate cancer: Validating assays predictive of tumor response

Book Section

Danila, D. C.; Scher, H. I.
In Goodsaid, F.; Mattes, W. B. (Eds.) The Path from Biomarker Discovery to Regulatory Qualification (2013)

Fulltext@MSK | Save

Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: Results from an analysis of a randomized phase III trial

Journal Article

Ryan, C. J.; Molina, A.; Li, J. H.; Kheoh, T.; Small, E. J.; Haqq, C. M.; Grant, R. P.; de Bono, J. S.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Feasibility of long-term patient self-reporting of toxicities from home via the internet during routine chemotherapy

Journal Article

Judson, T. J.; Bennett, A. V.; Rogak, L. J.; Sit, L.; Barz, A.; Kris, M. G.; Hudis, C. A.; Scher, H. I.; Sabbatini, P.; Schrag, D.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Evaluation of a composite biomarker panel including circulating tumor cell (CTC) enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Heller, G.; Molina, A.; Attard, G.; McCormack, R.; Riisnaes, R.; Kheoh, T.; Fleisher, M.; Buyse, M.; de Bono, J. S.
European Journal of Cancer (2013)

Fulltext@MSK | Save

Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 AFFIRM trial comparing enzalutamide to placebo

Meeting Abstract

Scher, H.; Fizazi, K.; Sternberg, C. N.; Armstrong, A.; Bhattacharya, S.; Hirmand, M.; de Bono, J.
European Journal of Cancer (2013)

Fulltext@MSK | Save

Androgen receptor (AR) and AR-signaling directed therapies in the age of precision medicine

Meeting Abstract

Scher, H.
European Journal of Cancer (2013)

Fulltext@MSK | Save

CA184-043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT)

Meeting Abstract

Gerritsen, W. R.; Kwon, E. D.; Fizazi, K.; Bossi, A.; Van den Eertwegh, A.; Logothetis, C.; Scher, H. I.; Beer, T. M.; McHenry, M. B.; Gagnier, P.; more...
European Journal of Cancer (2013)

Fulltext@MSK | Save

Assessing the impact of prior treatments on the efficacy of enzalutamide (ENZ): A subanalysis of the phase 3 AFFIRM trial

Meeting Abstract

de Bono, J.; Fizazi, K.; Shore, N.; Taplin, M.; De Wit, R.; Stenzl, A.; Hirmand, M.; Franks, B.; Scher, H.
European Journal of Cancer (2013)

Fulltext@MSK | Save

Impact of prior antiandrogen exposure on clinical outcomes in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D)

Meeting Abstract

Bellmunt, J.; Yu, M. K.; Kheoh, T.; Taplin, M. E.; Davis, I. D.; Schnjvers, D.; Protheroe, A.; Molina, A.; de Bono, J. S.; Scher, H. I.
European Journal of Cancer (2013)

Fulltext@MSK | Save